Bioventus (NASDAQ:BVS) Releases Quarterly Earnings Results, Hits Expectations

Bioventus (NASDAQ:BVS) posted its quarterly earnings data on Monday. The company reported $0.17 earnings per share for the quarter, hitting the consensus estimate of $0.17, FiscalAI reports. Bioventus had a net margin of 9.36% and a return on equity of 28.08%. The company had revenue of $142.44 million during the quarter.

Here are the key takeaways from Bioventus’ conference call:

• Growth initiatives gained traction: PRP disposable-kit reorders surpassed capital-placement revenue, PNS conversion and physician-training metrics exceeded expectations, Ultrasonics posted strong double-digit growth, and international revenue increased 16%.
• Profitability and cash flow improved. Adjusted EBITDA margin expanded 70 basis points to 20%, adjusted EPS rose 13% to $0.17, operating cash flow reached $21 million, and net debt fell below $200 million after $65 million of year-to-date term-loan repayments.
• Full-year revenue guidance was reduced to $590 million–$595 million, primarily due to weaker-than-expected bone graft substitute sales, softness in spine procedures, distributor-addition delays, and competitive dynamics in synthetic products.
• The strategic review prompted by an unsolicited acquisition proposal and other expressions of interest remains ongoing; management provided no timeline or additional details and declined to answer questions on the process.

Bioventus Trading Down 1.3%

BVS opened at $13.15 on Tuesday. Bioventus has a 1-year low of $6.47 and a 1-year high of $15.89. The stock has a market capitalization of $1.11 billion, a PE ratio of 17.08, a PEG ratio of 1.87 and a beta of 0.64. The company has a current ratio of 1.69, a quick ratio of 1.17 and a debt-to-equity ratio of 0.83. The firm has a 50-day moving average price of $13.68 and a two-hundred day moving average price of $10.90.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on BVS shares. Weiss Ratings raised Bioventus from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, October 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $15.00 price target on shares of Bioventus in a report on Monday, August 17th. Barrington Research set a $18.00 price target on Bioventus in a report on Thursday, August 6th. Craig Hallum reiterated a “buy” rating and issued a $18.00 price objective on shares of Bioventus in a research report on Thursday, August 6th. Finally, Canaccord Genuity Group boosted their price objective on Bioventus from $15.00 to $19.00 and gave the stock a “buy” rating in a research note on Monday, August 17th. Six research analysts have rated the stock with a Buy rating. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $16.80.

Institutional Trading of Bioventus

Several hedge funds have recently modified their holdings of the stock. Dimensional Fund Advisors LP raised its position in shares of Bioventus by 14.1% during the first quarter. Dimensional Fund Advisors LP now owns 873,138 shares of the company’s stock worth $7,971,000 after acquiring an additional 107,930 shares during the last quarter. Hillsdale Investment Management Inc. boosted its holdings in Bioventus by 148.7% in the first quarter. Hillsdale Investment Management Inc. now owns 671,139 shares of the company’s stock valued at $6,128,000 after acquiring an additional 401,230 shares during the last quarter. Engine Capital Management LP bought a new position in Bioventus in the first quarter valued at about $2,876,000. Lazard Asset Management LLC increased its position in Bioventus by 12.9% in the first quarter. Lazard Asset Management LLC now owns 305,517 shares of the company’s stock worth $2,789,000 after purchasing an additional 35,008 shares during the period. Finally, Sei Investments Co. increased its position in Bioventus by 160.7% in the first quarter. Sei Investments Co. now owns 289,648 shares of the company’s stock worth $2,644,000 after purchasing an additional 178,539 shares during the period. 62.94% of the stock is owned by institutional investors.

Bioventus News Roundup

Here are the key news stories impacting Bioventus this week:

• Positive Sentiment: Bioventus reported third-quarter adjusted EPS of $0.17, matching the analyst consensus and improving from $0.15 a year earlier. The result marked the company’s sixth consecutive quarterly EPS result at or above expectations. Bioventus Matches Q3 Earnings Estimates
• Positive Sentiment: Management reaffirmed its 2026 adjusted EPS outlook of $0.75 to $0.79, suggesting profitability expectations remain intact even as the revenue outlook was reduced. Bioventus Reaffirms Adjusted EPS Outlook
• Neutral Sentiment: The company reported third-quarter revenue of approximately $142.4 million, along with a 9.36% net margin and 28.08% return on equity. The earnings call transcript provides additional management commentary on the quarter and 2026 outlook. Bioventus Reports Third Quarter Financial Results
• Negative Sentiment: Bioventus cut its 2026 revenue forecast to $590 million-$595 million after third-quarter sales missed expectations. The revision indicates weaker operating growth and was the primary reason investors reacted negatively to the report. Bioventus Shares Fall on Third-Quarter Sales Miss
• Negative Sentiment: Coverage highlighted that earnings growth is being supported more by debt paydown and related financial benefits than by stronger underlying operations. That raises concerns about the durability of profit growth while revenue momentum remains pressured. Bioventus Cuts Revenue Outlook

Bioventus Company Profile

Bioventus Inc is a medical device and biologics company focused on developing and commercializing products that support bone healing, joint health and surgical recovery. Its portfolio is designed to help healthcare professionals treat musculoskeletal conditions and improve patient outcomes through noninvasive therapies, injectable products and biologic solutions.

The company’s offerings include bone stimulation systems such as EXOGEN, which is used to support fracture healing, as well as injectable osteoarthritis treatments including DUROLANE and GELSYN-3.